Grootste objectieve website voor
 complementaire en alternatieve geneeskunde

IOCOB

Home > Extra > English Articles > Amyotrophic Lateral Sclerosis treated with Palmitoylethanolamide (Normast; PeaPure)

Amyotrophic Lateral Sclerosis treated with Palmitoylethanolamide (Normast; PeaPure)

Share |

An interesting new therapeutic approach for the rehabilitation and Amyotrophic Lateral Sclerosis hasl been presented in Milan, during the second day of the XII National Congress of SIRN, the Italian Society of Neurological Rehabilitation.

The new hope in the treatment of ALS, neuro-degenerative disease that affects about one in every 100 (mostly men of middle or advanced age), and in 5% of cases are familial, comes from "palmitoylethanolamide" (PEA).

It is an endogenous compound with anti-inflammatory effect cannabinergico, discovered years ago by Italian scientists in the group that included, among others, the Nobel Prize Professor Rita Levi Montalcini.

PEA for ALS: further information 

Palmitoylethanolamide is available in the Netherlands as a food supplement, up to November 2012 as Normast and from November 2012 onwards as a new supplement, under the brandname PeaPure.

There are some important differences between Normast and PeaPure , but both supplements contain the body own anti-inflammatory compound palmitoylethanolamide.

In PeaPure you find in one package 30 capsules of 400 mg pure palmitoylethanolamide, without any other pharmaceutical substance, nor sweeteners.

In Normast you find in one package either 20 sachets containing 600 mg palmitoylethanolamide with ca 300 mg sorbitol (a sweetener) or a package with 20 tablets containing palmitoylethanolamide and magnesium stearate and other farmaceutical fillers.

The capsules of PeaPure are specially designed to be used either for obtaining filely powdered palmitoylethanolamide, to administer under the tongue (the capsule has been developed so that opening is easy and one can sprinkel the powder or directly in the mouth, or on a spoon and then under the tongue). The company developed PeaPure without any sweetener, because patients gave the input that the sweetener induced sometimes diarree. Or the sweetener, most of the time, induced so much slime/saliva in the  mouth, that it was difficult not to swallow.

Russell Science Ltd therefore developed this content of the capsule, the pure palmitoylethanolamide itself,  with a neutral taste by not adding sorbitol, to not attrack saliva and avoid the side effect of diarree.

How to take PEA in the ALS?

The best is to start with either Normast in 2 times 600 mg sachets or  with 3 capsules of PeaPure 400 mg and sprinkel the powder in the mouth. After the second day double the dose, and use 3 times 2 capsules. After 10 days, if it is convenient, one can swallow a capsule three times a day and use also the pwder from 3 capsules three times a day under the tongue.

If started with Normast powder, add Normast 600 mg tablets after a week, to increase the dose, or even double the dose.

 

Discovery is the author of Dr. Simonetta Clemente, the Rehabilitation Specialist who directs the Center for Rehabilitation of Macon ASL of Nuoro, assisted by a team of professionals where women reign supreme: Anna Carmela Pireddu, physiatrist, Giantonella Puggioni, internist, physiotherapists and Roberta Erdas, Sebastiano Rossi and Silvana Mastinu. The study will be presented in poster session, which is well suited to represent the results obtained through the numerous and significant photographic images. Since November of last year two patients with ALS (sporadic form in one case and another in the hereditary form), diagnosed with certainty at prestigious universities, have been subjected to administration of PEA.

"My goal – explains Dr. Clement – was to improve the effects of rehabilitation, that in ALS patients is rendered completely ineffective due to the degeneration of motor neurons and progressive muscle atrophy." "

The study – continues Clement – has shown that the PEA determines an immediate motor effect, blocking the progression of the disease, while the patient has a subjective perception of improvement and can do things which before were closed. This effect allows you to implement a rehabilitation plan that quickly determines the functional recovery, accompanied by the reappearance of the muscles. Of course, two cases are few. I hope that, after the Congress, it is possible to begin a multicenter research protocol with patients at different stages of severity, experiencing the active ingredient together with a targeted rehabilitation in order to drive the re-innervation, as in the two cases described ‘ .

The Director General of the Health of Nuoro, Dr. Antonio Maria Soru, expressed great satisfaction with the interesting therapeutic prospects identified:

"This is a first result that rewards the work of a respected professional company and the team that ‘has assisted in the study. But it is also an added incentive to encourage us all to support even more research and enhancing the many professionals working within the ASL of Nuoro, to contribute to improving care and quality of life for patients. "

Geef een reactie

Het e-mailadres wordt niet gepubliceerd. Verplichte velden zijn gemarkeerd met *